NRX Pharmaceuticals Inc
NRXP2.695USD
+0.105+4.05%
交易中 （美东）报价延迟15分钟
46.14M总市值
亏损市盈率 TTM
关于 NRX Pharmaceuticals Inc 公司
NRX Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司。该公司正在基于其 N-甲基-D-天冬氨酸 (NMDA) 平台开发用于治疗中枢神经系统疾病的疗法，特别是自杀性双相抑郁症、慢性疼痛和创伤后应激障碍 (PTSD)。该公司有两种主要化合物，NRX-100（氯胺酮的专有形式）和 NRX-101（D-环丝氨酸 (DCS) 和鲁拉西酮的固定剂量组合）。该公司正在开发 NRX-101，这是美国食品药品管理局 (FDA) 指定的用于治疗自杀性治疗抵抗性双相抑郁症和慢性疼痛的试验性疗法。NRX-101 是一种联合 NMDA/5-HT2A 靶向药物，旨在治疗抑郁症和自杀意念，由口服固定剂量的 DCS 和鲁拉西酮组合组成。其 NRX-100 是外消旋氯胺酮，是一种通用麻醉剂。该公司还致力于新产品 NRX-102 的开发。
公司简介
公司代码NRXP
公司名称NRX Pharmaceuticals Inc
上市日期Nov 20, 2017
CEODr. Jonathan C. Javitt, M.D.
员工数量- -
证券类型Ordinary Share
年结日Nov 20
公司地址1201 Orange Street
城市WILMINGTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编19801
电话14842546134
网址https://www.nrxpharma.com/
公司代码NRXP
上市日期Nov 20, 2017
CEODr. Jonathan C. Javitt, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
Dr. Dennis Mcbride
Dr. Dennis Mcbride
Independent Director
Independent Director
--
--
Mr. Matthew P. Duffy
Mr. Matthew P. Duffy
Chief Business Officer
Chief Business Officer
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Jonathan C. Javitt, M.D.
Dr. Jonathan C. Javitt, M.D.
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
1.52M
-0.01%
Mr. Chaim Hurvitz
Mr. Chaim Hurvitz
Independent Director
Independent Director
221.48K
--
Mr. Michael (Mike) Taylor
Mr. Michael (Mike) Taylor
Independent Director
Independent Director
--
--
Mr. Patrick J. Flynn
Mr. Patrick J. Flynn
Independent Director
Independent Director
--
--
Mr. Riccardo (Rick) Panicucci
Mr. Riccardo (Rick) Panicucci
Chief Manufacturing and Technology Officer
Chief Manufacturing and Technology Officer
--
--
Mr. Michael S. (Mike) Abrams
Mr. Michael S. (Mike) Abrams
Chief Financial Officer and Treasurer
Chief Financial Officer and Treasurer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月20日 周日
更新时间: 7月20日 周日
持股股东
股东类型
持股股东
持股股东
占比
Javitt (Jonathan C)
8.77%
Anson Funds Management LP.
6.82%
Glytech LLC
5.57%
The Vanguard Group, Inc.
2.25%
AdvisorShares Investments, LLC
1.66%
Other
74.93%
持股股东
持股股东
占比
Javitt (Jonathan C)
8.77%
Anson Funds Management LP.
6.82%
Glytech LLC
5.57%
The Vanguard Group, Inc.
2.25%
AdvisorShares Investments, LLC
1.66%
Other
74.93%
股东类型
持股股东
占比
Individual Investor
10.31%
Hedge Fund
6.99%
Corporation
5.57%
Investment Advisor/Hedge Fund
3.96%
Investment Advisor
2.29%
Research Firm
0.09%
Other
70.78%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
66
5.05M
29.22%
+1.46M
2025Q1
66
4.06M
26.08%
+505.82K
2024Q4
70
3.94M
22.32%
-356.61K
2024Q3
83
3.57M
28.23%
-628.46K
2024Q2
86
3.38M
32.03%
-634.67K
2024Q1
92
3.27M
34.30%
-835.14K
2023Q4
98
3.31M
81.28%
-805.62K
2023Q3
101
3.31M
42.19%
-663.76K
2023Q2
103
3.89M
52.92%
+527.79K
2023Q1
100
3.14M
46.14%
-970.16K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Javitt (Jonathan C)
1.52M
8.77%
-199.00
-0.01%
Apr 29, 2025
Anson Funds Management LP.
1.18M
6.82%
+993.40K
+535.06%
Mar 31, 2025
Glytech LLC
963.48K
5.57%
+963.48K
--
Apr 29, 2025
The Vanguard Group, Inc.
388.93K
2.25%
+148.61K
+61.84%
Mar 31, 2025
AdvisorShares Investments, LLC
286.80K
1.66%
-23.52K
-7.58%
Mar 31, 2025
Hurvitz (Chaim)
221.48K
1.28%
+1.00
+0.00%
Apr 29, 2025
Geode Capital Management, L.L.C.
134.66K
0.78%
+60.41K
+81.35%
Mar 31, 2025
Marshall Wace LLP
89.09K
0.52%
+89.09K
--
Mar 31, 2025
Flynn (Patrick John)
44.45K
0.26%
-14.58K
-24.70%
Apr 29, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
AdvisorShares Psychedelics ETF
7.9%
iShares Micro-Cap ETF
0.01%
AdvisorShares Psychedelics ETF
占比7.9%
iShares Micro-Cap ETF
占比0.01%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
公告日期
类型
比率
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
Mar 28, 2024
Merger
10<1
